NR1H4 and primary biliary cholangitis: Tropifexor (LJN452) is a non-bile acid FXR agonist investigated in a double-blind, randomized, placebo-controlled, phase 2 study (“A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients”, NCT02516605) that evaluated the safety and the efficacy of different doses of Tropifexor (30 μg, 60 μg, and 90 μg) in patients with an inadequate response to UDCA [33].